Synpac

Synpac is a pharmaceutical company based in Taiwan that is internationally recognized for its pivotal role in the development of the first treatment for Pompe disease. The company funded foundational research at Duke University for a recombinant human acid alpha-glucosidase (rhGAA) and subsequently licensed the technology to Genzyme (now Sanofi), resulting in the commercialization of Myozyme and Lumizyme. Historically, Synpac was a major global player in the bulk antibiotic market, operating large-scale penicillin manufacturing facilities in the United Kingdom and the United States before divesting those assets to DSM in 2000. Today, the company continues to operate through its affiliate, Synpac-Kingdom Pharmaceutical, focusing on the manufacture and distribution of a broad range of pharmaceutical products. Its business model emphasizes bridging the gap between academic discovery and commercial drug development through strategic licensing and investment. The company remains a significant example of how private investment in academic research can lead to breakthrough therapies for rare diseases.